Patient outcomes
| Outcomes . | OHI− . | OHI+ . | HR (95% CI) . | P value . |
|---|---|---|---|---|
| 1-Year OS, % (95% CI), all patients | 81 (70-89) | 33 (22-44) | 5.2 (3.0-8.8) | <.0001 |
| 1-Year EFS, % (95% CI), all patients | 58 (45-69) | 24 (14-35) | 2.9 (1.8-4.6) | <.0001 |
| 3-Year OS, % (95% CI), all patients | 80 (68-88) | 23 (13-35) | 5.4 (3.3-8.8) | <.0001 |
| 3-Year EFS, % (95% CI), all patients | 51 (36-64) | 11 (5-20) | 3.3 (1.1-5.1) | <.0001 |
| 1-Year OS, % (95% CI), patients with DLBCL | 90 (68-98) | 40 (19-60) | 8.7 (3-25) | .0006 |
| 1-Year EFS, % (95% CI), patients with DLBCL | 62 (40-79) | 30 (11-51) | 2.7 (1.1-6.4) | .02 |
| 1-Year OS, % (95% CI), patients with T-cell lymphoma | 66 (39-84) | 19 (5-38) | 3.6 (1.6-8.3) | .007 |
| 1-Year EFS, % (95% CI), patients with T-cell lymphoma | 39 (16-51) | 10 (2-27) | 2.6 (1.2-5.3) | .01 |
| Outcomes . | OHI− . | OHI+ . | HR (95% CI) . | P value . |
|---|---|---|---|---|
| 1-Year OS, % (95% CI), all patients | 81 (70-89) | 33 (22-44) | 5.2 (3.0-8.8) | <.0001 |
| 1-Year EFS, % (95% CI), all patients | 58 (45-69) | 24 (14-35) | 2.9 (1.8-4.6) | <.0001 |
| 3-Year OS, % (95% CI), all patients | 80 (68-88) | 23 (13-35) | 5.4 (3.3-8.8) | <.0001 |
| 3-Year EFS, % (95% CI), all patients | 51 (36-64) | 11 (5-20) | 3.3 (1.1-5.1) | <.0001 |
| 1-Year OS, % (95% CI), patients with DLBCL | 90 (68-98) | 40 (19-60) | 8.7 (3-25) | .0006 |
| 1-Year EFS, % (95% CI), patients with DLBCL | 62 (40-79) | 30 (11-51) | 2.7 (1.1-6.4) | .02 |
| 1-Year OS, % (95% CI), patients with T-cell lymphoma | 66 (39-84) | 19 (5-38) | 3.6 (1.6-8.3) | .007 |
| 1-Year EFS, % (95% CI), patients with T-cell lymphoma | 39 (16-51) | 10 (2-27) | 2.6 (1.2-5.3) | .01 |